Back row, left to right: James Atherton, Matthias Zimmermann, Kym Baker, Dr Anthony Stowers. Front row, left to right: Professor James McCluskey, Professor Sally Gras, Dr Richard Johnson A new Australian Research Council (ARC) Hub to help forge an internationally competitive Australian biopharmaceutical sector using digitisation and artificial intelligence (AI) in pharmaceutical manufacturing is being launched today at the University of Melbourne. ARC Acting CEO Dr Richard Johnson is officially launching the ARC Digital Bioprocess Development Hub – a five-year, $18 million research program, which has received $5 million in ARC funding, to advance scientific knowledge and allow an interdisciplinary team of engineers, scientists and computing specialists to develop new capabilities. These will include digitally-integrated, advanced and innovative manufacturing processes that capture and use big data and provide a platform for industry adoption. Australia’s biopharmaceutical manufacturing industry supplies a rapidly growing domestic and international market for pharmaceuticals and vaccines, and its 2022 sector valuation of AUD $12 billion is expected to grow as an ageing population, the need for onshore manufacturing capability and the commercialisation of our medical research all converge. The Hub involves collaboration between the University of Melbourne, University of Technology Sydney, RMIT University, global biotechnology company […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
